WBI Investments LLC Makes New $1.92 Million Investment in Royalty Pharma PLC $RPRX

WBI Investments LLC purchased a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 54,266 shares of the biopharmaceutical company’s stock, valued at approximately $1,915,000.

Other large investors have also made changes to their positions in the company. Smartleaf Asset Management LLC lifted its stake in shares of Royalty Pharma by 868.1% in the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 790 shares during the period. Financial Consulate Inc. purchased a new position in Royalty Pharma in the third quarter valued at about $35,000. Larson Financial Group LLC increased its holdings in Royalty Pharma by 31.9% in the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares in the last quarter. Richardson Financial Services Inc. acquired a new stake in shares of Royalty Pharma during the 3rd quarter valued at approximately $54,000. Finally, Farther Finance Advisors LLC lifted its position in shares of Royalty Pharma by 44.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,060 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 632 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on RPRX. TD Cowen restated a “buy” rating on shares of Royalty Pharma in a report on Friday, February 27th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a report on Thursday, December 11th. UBS Group upgraded Royalty Pharma from a “neutral” rating to a “buy” rating and set a $49.00 target price on the stock in a research report on Friday, January 30th. Citigroup upped their target price on Royalty Pharma from $48.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, January 27th. Finally, Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 14th. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma presently has an average rating of “Buy” and an average price target of $48.67.

Royalty Pharma Stock Up 0.0%

RPRX opened at $46.11 on Wednesday. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.88. The firm has a market cap of $26.60 billion, a P/E ratio of 34.16 and a beta of 0.40. Royalty Pharma PLC has a 52 week low of $29.66 and a 52 week high of $47.86. The business’s fifty day simple moving average is $43.49 and its 200 day simple moving average is $39.73.

Royalty Pharma (NASDAQ:RPRX) last announced its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.33 by $0.13. The firm had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. As a group, equities research analysts anticipate that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Friday, February 20th were given a $0.235 dividend. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.22. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date of this dividend was Friday, February 20th. Royalty Pharma’s dividend payout ratio (DPR) is presently 69.63%.

Insider Activity

In related news, EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $41.09, for a total transaction of $821,800.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP George W. Lloyd sold 30,654 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $38.50, for a total transaction of $1,180,179.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 568,150 shares of company stock valued at $23,366,062 over the last 90 days. Insiders own 18.90% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.